This site is intended for healthcare professionals
Drug news

FDA expands indication for Aczone for patients age 9 - 11 with acne

Read time: 1 mins
Last updated:16th Sep 2019
Published:12th Sep 2019
Source: Pharmawand

Almirall LLC announced the FDA approval of the expanded indication for Aczone 7.5% (dapsone gel) to include patients aged 9-11. Aczone 7.5% Gel is a prescription medicine used on the skin (topical) to treat inflammatory and non-inflammatory acne, previously approved in February 2016 for patients 12 and older.

The expanded approval was based on data from an open-label safety study to assess safety, pharmacokinetics, and treatment effect of Aczone Gel, 7.5% in 101 patients 9 to 11 years of age with acne vulgaris. Aczone 7.5% Gel was determined to be safe and effective in this patient population.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.